The National Institutes of Health (NIH) defines a Clinical Trial as a research study in which one or more human subjects are prospectively assigned to one or more interventions. Clinical trials help develop novel drugs (Investigational Products) by providing early access to patients who volunteer to participate in the research study.
Carolina BioOncology Institute and our expert Providers participate in the national clinical trials listed below. The eligibility criteria enables patients with advanced solid tumors to access these Investigational Products. Over the past 15 years, our Clinic has opened over 100 Oncology clinical trials and our experienced staff are happy to discuss options for determining trial eligibility Please view the list of trials below that are currently enrolling patients:
AbbVie M21-410
A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab.
AbbVie M24-742
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
Acrivon ACR-2316-101
Phase 1 study of ACR-2316 in subjects with advanced solid tumors
ClinicalTrials.gov link still pending
Apollo AP10CP01
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Arvinas ARV-806-101
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Aulos CP-AU-007-01
A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer
BioNTech BNT314-01
Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors
BioNTech BNT317-01
A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients with Advanced Solid Tumors
Bright Peak Therapeutics BPT567-101
Phase 1 Investigation of the Safety, Tolerability and Preliminary Antitumor Activity of BPT567, a Multifunctional PD1-IL18 Immunocytokine in Patients with Advanced Solid Tumors (SUMMIT-1)
Corbus CRB-701-01
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
CytoMx CTMX-2051-01
First In Human Study of CX-2051 in Advanced Solid Tumors
Dren Bio DR-0202-ONC-101
A Phase Ia/Ib, Multicenter, Dose Escalation/Expansion, Multiple Dose Study to Evaluate Safety and Activity of DR-0202 in Patients with Locally Advanced Metastatic, Relapsed, or Refractory Carcinomas
Duality Bio DB-1419-O-1001
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants with Advanced/Metastatic Solid Tumors
EMD Serono MS202650-0001
An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 in Combination with Topoisomerase 1 Inhibitor-based Regimens in Advanced Solid Tumors and Colorectal Cancer
ClinicalTrials.gov link still pending
ENSEM ETX-636-C-001
A Phase 1/2, Open-Label, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-Mutant-Selective PI3Kα Inhibitor, as Monotherapy and in Combination with Other Anticancer Therapies in Participants with Advanced Solid Tumors
Exelixis XB010-101
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors
ClinicalTrials.gov link still pending
Exelixis XB371-101
A Dose Escalation and Expansion Study of XB371 Administered in Participants with Locally Advanced or Metastatic Solid Tumors
Exelixis XB628-101
A Phase 1 Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Incyte INCB177054-101
A Phase 1/2, Open-Label, Multicenter Study of INCB177054 in Participants with Select Advanced or Metastatic Solid Tumors
Multitude Therapeutics AMT-116-01
AMT-116 in Patients With Advanced Solid Tumors
Nuvation NUV-1511-01
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Qurgen SON-DP-A001-ST
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Revolution Medicines RMC-9805-01
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumor
Sairopa SRP-22C102
An Open-Label, Multicenter, Multi-Arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults with Advanced Solid Tumors.
Terremoto TER-2013-C01
A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Teva TV56278-ONC-10203
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Solid Tumors
Trethera TRE515-T-02
A Phase 1, Open-Label, First-In-Human, Dose-Escalation Study with Expansion to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered TRE-515 in Subjects with Solid Tumors.
